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Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis and limited ther-
apeutic options. Over the last decade, pan-genomic analyses of genetic and epigenetic 
alterations and genome-wide expression profile studies allowed major advances in the 
understanding of the molecular genetics of ACC. Besides the well-known dysfunctional 
molecular pathways in adrenocortical tumors, such as the IGF2 pathway, the Wnt path-
way, and TP53, high-throughput technologies enabled a more comprehensive genomic 
characterization of adrenocortical cancer. Integration of expression profile data with 
exome sequencing, SNP array analysis, methylation, and microRNA (miRNA) profiling led 
to the identification of subgroups of malignant tumors with distinct molecular alterations 
and clinical outcomes. miRNAs post-transcriptionally silence their target gene expres-
sion either by degrading mRNA or by inhibiting translation. Although our knowledge of 
the contribution of deregulated miRNAs to the pathogenesis of ACC is still in its infancy, 
recent studies support their relevance in gene expression alterations in these tumors. 
Some miRNAs have been shown to carry potential diagnostic and prognostic values, 
while others may be good candidates for therapeutic interventions. With the emergence 
of disease-specific blood-borne miRNAs signatures, analyses of small cohorts of patients 
with ACC suggest that circulating miRNAs represent promising non-invasive biomarkers 
of malignancy or recurrence. However, some technical challenges still remain, and most 
of the miRNAs reported in the literature have not yet been validated in sufficiently pow-
ered and longitudinal studies. In this review, we discuss the current knowledge regarding 
the deregulation of tumor-associated and circulating miRNAs in ACC patients, while 
emphasizing their potential significance in pathogenic pathways in light of recent insights 
into the role of miRNAs in shaping the tumor microenvironment.
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iNTRODUCTiON
Adrenocortical cancer is a rare and aggressive malignancy (with an incidence of 0.7–2.0 cases per 
million per year). Patients with adrenocortical carcinoma (ACC) generally have a poor prognosis, 
with a 5-year survival rate ranging from 15 to 30% in most series (1). Most patients present with 
advanced disease or develop local recurrence and distant metastasis post-operatively. In addition, 
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despite the development of systematic classification algorithms 
(2), it is sometimes challenging to discriminate malignant 
tumors from their benign counterparts. Currently, the only 
curative approach to localized ACC is complete tumor resec-
tion. Adjuvant mitotane therapy has been shown to improve 
recurrence-free survival following complete surgical resection 
(3).Nevertheless, this adrenolytic drug causes significant toxicity 
and adverse effects (4). Adjuvant radiation therapy showed no 
advantage in terms of overall survival (5–7). In metastatic dis-
ease, mitotane has produced very limited objective response (8) 
and remains the only drug approved by the U.S Food and Drug 
Administration (FDA) and the European Medicine Executive 
Agency (EMEA). The First International Randomized trial in 
locally advanced and Metastatic Adrenocortical Carcinoma 
Treatment (FIRM-ACT) reported that the combination of 
mitotane with the chemotherapeutic agents etoposide–cispl-
atin–doxorubicin was associated with a better progression-free 
survival than the association of mitotane with streptozotocin 
(9). However, the overall survival did not differ between both 
arms. In light of these therapeutic failures, molecular targeted 
therapies have been tested in patients with metastatic ACC. 
These approaches include epidermal growth factor receptor 
(EGFR) inhibitors (10), anti-vascular growth factor antibodies 
(bevacizumab) (11), and tyrosine kinase inhibitors (Sorafenib, 
Sunitinib) (12, 13). More recently, drugs targeting the IGF2/
IGF-1R signaling pathway have been evaluated (14–16). All 
these targeted therapies yielded disappointing results in terms of 
progression-free and overall survival. In this context, there is a 
critical need for additional tools to improve diagnosis and prog-
nosis and to explore new targeted therapies. Over the last decade, 
gene expression profiling using DNA microarray analysis has 
emerged as a useful technique for tumor classification (17–25). 
Increased IGF2 expression was identified in most studies as one 
of the most dominant transcriptional change specifically present 
in ACC relative to benign tumors (adenomas, ACA) and normal 
adrenal (NA). More recently, an integrated genomic characteri-
zation of ACC, combining exome sequencing, SNP arrays, DNA 
methylation analysis, mRNA expression arrays, and microRNAs 
(miRNAs) sequencing provided a comprehensive overview 
of known drivers genes (CTNNB1, TP53, CDKN2A, RB1, and 
MEN1) and newly identified altered pathways (ZNRF3, DAXX, 
TERT, and MED12) in ACC (26). It appeared that aggressive and 
non-aggressive ACC are two distinct diseases with specific gene 
signatures and alterations.
In mammals, miRNAs were discovered a decade ago as an 
abundant class of small non-coding RNA (18–24 nt in length) 
that silence their target genes at the post-transcriptional level, 
either by degrading mRNA or by inhibiting translation (27). 
Comparative sequence analyses combined to computational 
methods predict that miRNAs could regulate the expression 
of more than 50–60% of human coding genes (28). The latest 
version of miRBase (Release 21, June 2014) has annotated over 
2000 miRNA sequences in the human genome and novel ones 
are reported at a constant rate as more tissues are sequenced to 
greater depth. The biogenesis of miRNAs consists of multiple 
steps (29) (Figure 1). The primary miRNA (pri-miRNA) tran-
script is transcribed by RNA polymerase II, then cleaved by the 
complex Drosha to release a hairpin-structured miRNA precur-
sor (pre-miRNA) in the nucleus. Pre-miRNA is transported from 
the nucleus to the cytoplasm by exportin-5-Ran-GTP-dependent 
double-stranded (ds) RNA-binding protein then processed into a 
short ds miRNA duplex by the ribonuclease III Dicer. Following 
unwinding of the duplex, the resultant guide strand mature 
miRNA is preferentially assembled into the RNA-induced 
silencing complex (RISC) composed of Dicer, Argonaute 2 
(Ago2), and the dsRNA-binding protein TRBP. The association 
of the miRNA–RISC complex to complementary sequences in 
the 3′-untranslated region (3′-UTR) of target mRNA leads to 
inhibition of protein translation or degradation of the mRNA. 
More recently, it has been shown that miRNAs may target 
protein coding as well as 5′-UTR regions (30). An additional 
layer of complexity has been added since miRNAs were dem-
onstrated to modulate gene expression at transcriptional level 
through their interaction with the transcription machinery or 
promoter sequences (31). Many miRNAs exhibit tissue-specific 
pattern of expression, suggesting that they play critical role in 
tissue and organ development, function, and maintenance. Each 
miRNA can control hundreds of genes and a single transcript 
harbors binding sites for several miRNAs. Due to their potential 
multi-target actions, it is not surprising that miRNAs regulate 
a plethora of basic biological mechanisms, such as cell cycle 
control, apoptosis, cell proliferation, differentiation, migration, 
and invasion, that impact systems biology in cancer.
A link between miRNAs and cancer was brought by the 
seminal observation of Croce’s group who reported that miR-15 
and miR-16, two miRNAs located in chromosome 13 (13q14) 
are frequently deleted in chronic lymphocytic leukemia (CLL) 
and function as tumor suppressors (32, 33). Since then, miRNAs 
have been studied most intensively in the field of cancer research 
and growing evidence suggests that altered miRNA expression is 
involved in the pathogenesis of cancers. The causes of the deregu-
lation of miRNA expression in cancer cells are only partially 
elucidated. So far, at least three different mechanisms that could 
function independently or together have been described. The 
first one is that half of the known miRNAs are located in regions 
of chromosomal instability associated with cancer, including 
regions of loss of heterozygosity (LOH), regions of amplification, 
and fragile sites (34). The second mechanism involves epigenetic 
regulation of miRNA expression. DNA hypomethylation, CpG 
island hypermethylation and histone-modification losses have 
been shown to also affect miRNA expression (35). For exam-
ple, histone deacetylase inhibition in breast cancer cells was 
followed by the extensive alteration of miRNA levels (36). The 
third mechanism is abnormalities in miRNA-processing genes 
and proteins (35). As the machinery involved in the biogenesis 
and maturation of miRNAs involve multiple protein complexes, 
one can anticipate that alterations of these proteins should have 
dramatic effects on miRNA expression. An analysis of gene 
expression in a wide range of primary tumors revealed that the 
downregulation of miRNAs observed in cancer was due to a 
failure at the Drosha processing step although the mechanisms 
underlying these dysregulations were not elucidated in this 
study (37). Interestingly, it was subsequently reported that p53 
promotes the Drosha-mediated processing of certain miRNAs 
FiGURe 1 | Biogenesis and function of microRNAs. miRNA genes are transcribed as primary miRNAs (Pri-miRNA) by polymerase II (Pol II) in the nucleus. 
Pri-miRNAs are cleaved by the RNAse III endonuclease DROSHA and its proteins partners (DROSHA complex) to produce the 60- to 70-nt stem–loop precursor 
miRNAs (pre-miRNAs). The pre-miRNAs are then exported to the cytoplasm by exportin 5 and further processed by DICER1, a type III RNAse that produces the 
22-nt mature miRNAs. One strand of the mature miRNA is selectively loaded into the miRNA-induced silencing complex (RISC), which contains DICER1, Argonaute 
(AGO) proteins, and the transactivation-responsive RNA-binding protein (TRBP). In the cytoplasm, mature miRNAs bind essentially to the 3′-UTR of the target mRNA 
and repress its expression through both translational repression and mRNA destabilization. Some miRNAs have been shown to bind to the open reading frame 
(ORF) and the 5′-UTR of the target mRNA, and to activate or repress its translation efficiency. In the nucleus, miRNAs were shown to bind to gene promoter to 
regulate gene expression. miRNAs are also released into the extracellular space and are possibly involved in intercellular communication when transferred to 
target cells. Extracellular miRNAs are encapsulated within microvesicles, such as exosomes, or bound to RNA-binding proteins, such as Ago2, or lipoproteins, 
such as HDL.
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with growth-suppressive function (38). Consequently, p53 gene 
mutations may lead to decreased processing of pri-miRNAs by 
Drosha and decreased levels of mature miRNAs in cancer cells.
The abnormal levels of miRNAs in tumors have important 
pathogenic consequences: miRNAs that are overexpressed in 
tumors contribute to oncogenesis by downregulating tumor 
suppressor genes, whereas underexpressed miRNAs contribute 
to oncogene expression. However, certain miRNAs may function 
as tumor suppressors or oncogenes depending on the cell-type-
specific microenvironment, which may provide a different rep-
ertoire of available target genes. Identification of specific miRNA 
expression patterns for different tumor histological types is a 
useful complement for the classification of tumors that otherwise 
cannot be accurately diagnosed by classical morphology-based 
methods. Interestingly, Lu et al. showed that the expression levels 
of 217 miRNAs classified poorly differentiated tumors better than 
information obtained from microarray analysis of about 16,000 
mRNAs (39). The diagnostic power of these miRNA profiles 
strongly support the key role of miRNAs in developing and 
maintaining cellular fates. On the other hand, the potential role 
of miRNAs as prognostic and predictive biomarkers in cancer 
patient management has been suggested by numerous studies. 
One of the most recent exciting findings is that cell-derived 
miRNAs exist with remarkable stability in various types of body 
fluids, including blood. Circulating miRNAs are encapsulated in 
microparticles (microvesicles, exosomes, and apoptotic bodies) 
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or associated with RNA-binding proteins (Ago2), or lipoprotein 
complexes (high-density lipoproteins) (40). Although previ-
ously considered to be cellular waste products, recent studies 
have demonstrated that exosomes are “bioactive vesicles” that 
promote intercellular communication by shuttling molecules 
between cells (41). Importantly, specific circulating miRNA 
concentrations correlate with the development and progression 
of cancer (42). Circulating miRNAs fulfill several properties of 
non-invasive and good biomarkers, such as availability in various 
body fluids, sequence conservation between human and various 
preclinical models, and available sensitive technologies for their 
quantification. The technologies used to measure miRNA levels 
include microarray, next-generation sequencing (NGS), and 
reverse-transcriptase quantitative Polymerase Chain Reaction 
(RT-qPCR). Both microarray and NGS-based platforms are suit-
able for screening and discovery purposes, but qPCR remains 
the top choice for validation and clinical tests. Regarding miRNA 
target identification, it is worth mentioning that this task is largely 
limited due to the imperfect complementarity of miRNAs and 
target transcripts. Canonical miRNA targeting is characterized 
by the perfect pairing of the miRNA’s seed sequence, usually 
comprising 2–7 nt at the 5′-end of the miRNA, which is accom-
panied by base pairing at the miRNA’s 3′-end (43). However, 
non-canonical targeting that lacks continuous seed pairing, but 
relies on increased complementarity toward the miRNA’s center 
and/or 3′-end has been reported (44). Notably, only canonical 
targeting of miRNAs can be predicted by available in silico tools. 
Although these algorithms provide useful insights in some cases, 
these approaches remain challenging. Integrated transcriptome, 
proteome, and miRnome analyses to identify functional mRNA 
targets of miRNAs with altered expression may add valuable 
information on changes in gene regulation. On the other hand, 
because miRNAs affect the expression of multiple genes and 
thereby tune multiple steps in oncogenic pathways, they rep-
resent interesting therapeutic targets. The potential for using 
miRNAs in cancer therapy is now being explored thanks to the 
new advances in delivery of miRNA inhibitors or miRNA mimics 
(45). An overview of miRNA research tools for isolation, detec-
tion, target determination, regulation, and clinical applications is 
presented in Figure 2. In the present review, we summarize the 
findings related to miRNA deregulation in ACC with a focus on 
specific miRNA members and discuss their intrinsic merits and 
challenges for their use as diagnostic and prognostic biomarkers 
as well as potential therapeutic targets in ACC.
GLOBAL CHANGeS iN miRNA 
eXPReSSiON AND iN miRNA BiOGeNiC 
MACHiNeRY iN ADReNOCORTiCAL 
CANCeR
Due to the rarity of adrenocortical cancer, our understanding of 
the relevance of miRNAs in the pathogenesis of this disease is 
still in its infancy. While the role of miRNAs in the development 
and progression of a most common cancer, such as lung cancer, 
has reached several hundred publications in Medline, about 30 
studies have been published on miRNAs in ACC. The number of 
validated target genes for deregulated miRNAs in ACC remains 
very limited (46–50). Thus, in-depth analyses of the mechanisms 
underlying miRNA deregulations in ACC and their role in aber-
rant gene expression remain to be conducted. Network algorithms 
could be effective in testing for potential associations between 
miRNA clusters and gene expression alterations. For example, 
integration of certain dysregulated miRNAs into gene networks 
established from ACC omics datasets revealed their potential role 
in specific signaling pathways in adrenocortical cancer (51). A 
new intricate dimension has been added to miRNA regulation 
since it was discovered that miRNAs are themselves targeted by 
regulatory RNA species (52). Recent studies identified compet-
ing endogenous RNAs (ceRNAs) or natural miRNA sponges 
that titrate miRNA availability (53). Such miRNA sponges bind 
miRNAs and competitively sequester them from their physiologi-
cally relevant targets. This class of sponges includes endogenously 
transcribed pseudogenes, long non-coding RNAs (lncRNA), and 
recently discovered circular RNAs. They may act in large complex 
networks in conjunction with miRNAs to regulate protein levels. 
Interestingly, lncRNA dysregulation has been recently reported in 
adrenocortical tumors (54). The impact of lncRNAs on miRNA 
expression and function in ACC awaits further investigations.
Besides chromosomal alterations, major dysfunctional path-
ways in ACC, such as somatic mutations of the tumor suppressor 
gene TP53, overexpression of IGF2, and activation of the Wnt/β 
catenin signaling pathway, are likely to impact miRNA expression. 
Global alterations in the expression of miRNAs in ACC com-
pared to ACA or to normal adrenocortical tissue (NA) have been 
reported in nine retrospective studies conducted in adult patients 
(Table 1). Only one study has assessed the expression of a set of 
miRNAs in childhood adrenocortical tumors (46). Microarrays 
and qPCR have been the main strategies applied to investigate 
the link between miRNAs and adrenocortical tumors (Table 1). 
More recently, NGS brought a new informative landscape on 
miRNA expression in adrenocortical cancer (26) (discussed 
below). Despite this rapid progress, many challenges related to 
miRNA biomarker development for ACC include variations in 
sample collection and processing, in quantification methods and 
normalization controls as well as in data analysis. Independent 
studies using small cohorts and different miRNA detection 
platforms have often reported poorly overlapping results. So far, 
none of the miRNAs identified as potential biomarkers for ACC 
have been validated in appropriately powered clinical studies. 
International collaborative studies using large cohorts, standard-
ized procedures, and consensual rules for statistical analyses 
would enable to establish robust miRNA signatures. In this con-
text, the use of RNA sequencing would enable to address different 
questions that remain unanswered by RT-qPCR or microarray 
approaches, such as the detection of single nucleotide variants 
and copy number as well as the discovery of novel miRNAs. In 
addition, RNA sequencing is not biased by thermodynamics, a 
drawback of qPCR and microarrays platforms. However, potential 
limitations of NGS include the high cost and the computational 
infrastructure needed for data analysis and interpretation. A 
detailed description of miRNAs that were found deregulated in 
ACC has been provided in previous reviews (55, 56). Here, we will 
focus on miRNAs that were consistently reported as differentially 
FiGURe 2 | An overview of miRNA research tools for isolation, detection, target determination, regulation, and clinical applications.
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expressed in tumor tissue and serum or plasma among different 
studies.
miR-483-5p and miR-483-3p
miR-483-5p overexpression in ACC was consistently found in 
seven studies out of nine, whereas miR-483-3p overexpression 
was reported in five studies only (Table 1). Increased expression 
of miR-483-5p also identified a subgroup of patients that had 
significantly poorer prognosis (57). Upregulation of miR-483-5p 
was also observed in malignant pheochromocytomas as com-
pared to benign tumors and associated with a poorer disease-free 
survival (64). miR-483 gene, which encodes both strands 5p and 
3p, is located at 11p15.5 within the second intron of IGF2 gene. 
The high expression of miR-483-5p observed in ACC was found 
to be correlated with the high expression of IGF2 (58). However, 
the potential contribution of others mechanisms to miR-483-5p 
overexpression remains to be evaluated. Indeed, a functional 
β-catenin-dependent and IGFI2-independent-transcription start 
site located upstream of miR-483 locus has been reported in 
hepatocarcinoma and colon cancer cells (65). Oncogenic features 
of miR-483-5p and miR-483-3p have been suggested in Wilms’ 
tumors as well as in liver, breast, and colon cancers (66, 67). 
Veronese et al. further demonstrated that the oncogenic mecha-
nism of miR-483-3p could be partially attributed to its ability 
to modulate the pro-apoptotic protein BBC3/PUMA, thereby 
protecting cells from apoptosis (66). Similar observations were 
subsequently made in ACC by Ozata et  al. in the NCI-H295R 
ACC cell line (47). In the same study, downregulation of both 
miR-483-5p and miR-483-3p resulted in decreased proliferation. 
Using in situ hybridization, Wang et al. observed that miR-483-3p 
was overexpressed in 68% (17 of 25) of ACCs and in 12% (3 of 25) 
of ACAs (68). A combination of miR-483-3p and Smad4 expres-
sion improved the diagnostic accuracy provided by the Weiss 
score system. Interestingly, miR-483-3p but not miR-483-5p was 
found to be upregulated in childhood adrenocortical tumors (46). 
It is worth mentioning that overexpression of miR-483-5p or miR-
483-3p in several human neoplasms suggests a wider involvement 
of this miRNA in human tumorigenesis. However, the dramatic 
increase of IGF2 and miR-483 expression in ACC (up to several 
hundreds of times as compared to ACA or NA) when compared 
to that of other cancers suggest a critical role for IGF2 locus in 
adrenocortical cancer development and progression. miR-483-5p 
but not miR-483-3p was recently shown to induce epithelial to 
mesenchymal transition (EMT) and to promote lung adenocar-
cinoma cell migration in vitro by targeting Rho GDP dissociation 
inhibitor alpha (RhoGDI1) and activated leukocyte cell adhesion 
molecule (ALCAM) (69). In vivo, miR-483-5p promotes lung 
adenocarcinoma metastases (69). Interestingly, IGF2 overexpres-
sion was not sufficient for tumor formation in transgenic mouse 
models (70–72). Along the same line, Veronese et al. showed that 
miR-483-3p inhibition could suppress tumorigenicity of HepG2 
cells while no antitumor effect was elicited by inhibition of IGF2 
(66). These results clearly indicate crucial oncogenic functions 
of miR-483 within IGF2 gene and might explain why transgenic 
animals for IGF2 overexpression did not develop tumors as IGF2 
transgenes were lacking miR-483 locus.
miR-503
miR-503 was found significantly overexpressed in ACCs as 
compared to their normal and benign counterparts (26, 47, 
61, 62) and in childhood adrenocortical tumors (46). Survival 
analysis indicated that high miR-503 was significantly associ-
ated with poor survival of ACC patients. In the study by Chabre 
et  al., overexpression of miR-503 in ACC was observed in the 
discovery cohort but did not reach significance (59). miR-503 
overexpression has been reported in retinoblastoma (73) as well 
as in parathyroid carcinoma (74). The role of miR-503 in ACC 
pathogenesis deserves further investigation. Indeed, miR-503 
TABLe 1 | Significantly deregulated microRNAs in adrenocortical cancer.
validated miRNA in ACC 
compared to ACA or NA
Sample type and  
method
Cohort composition Signature Reference
miR-483-5p Microarray/RT-qPCR 22 ACC, 27 ACA, 6 NA ↑c Soon et al. (24, 57)
Microarray/RT-qPCR 10 ACC, 26 ACA, 21 NA ↑ Patterson et al. (58)
Microarray/RT-qPCR 25 ACC, 43 ACA, 10 NA ↑ Ozata et al. (47)
RT-qPCR 18 ACCa, 10 ACA, 3 NA ↑ Chabre et al. (59)
RT-qPCR 51 ACC ↑ Duregon et al. (60)
NGS 45 ACCa, 3 NA ↑ Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↑ Feinmesser et al. (61)
miR-483-3p Microarray/RT-qPCR 10 ACC, 26 ACA, 21 NA ↑ Patterson et al. (58)
Microarray/RT-qPCR 25 ACC, 43 ACA, 10 NA ↑ Ozata et al. (47)
RT-qPCR 51 ACC ↑ Duregon et al. (60)
NGS 45 ACCa, 3 NA ↑ Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↑ Feinmesser et al. (61)
miR-210 TLDA 7ACC, 19 ACA, 10 NA ↑ Tombol et al. (25, 62)
Microarray/RT-qPCR 25 ACC, 43 ACA, 10 NA ↑ Ozata et al. (47)
RT-qPCR 51 ACC ↑b,c Duregon et al. (60)
NGS 45 ACCa, 3 NA ↑b Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↑ Feinmesser et al. (61)
miR-503 TLDA 7ACC, 19 ACA, 10 NA ↑ Tombol et al. (25, 62)
Microarray 25 ACC, 43 ACA, 10 NA ↑c Ozata et al. (47)
NGS 45 ACCa, 3 NA ↑b Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↑ Feinmesser et al. (61)
miR-184 TLDA 7ACC, 19 ACA, 10 NA ↑ Tombol et al. (25, 62)
NGS 45 ACCa, 3 NA ↑b Assie et al. (26)
miR-21 Microarray/RT-qPCR 25 ACC, 43 ACA, 10 NA ↑ Ozata et al. (47)
miR-1202 id. id. ↑c id.
miR-1275 id. id. ↑c id.
miR-139-5p Microarray/RT-qPCR 12 ACCa, 6 ACA + validation cohort (18 ACCa, 10 ACA, 3 NA) ↑b Chabre et al. (59)
NGS 45 ACCa, 3 NA ↑b Assie et al. (26)
miR-376a Microarray/RT-qPCR 12 ACCa, 6 ACA + validation cohort (18 ACCa, 10 ACA, 3 NA) ↑b Chabre et al. (59)
NGS 45 ACCa, 3 NA ↑b Assie et al. (26)
miR-195 Microarray/RT-qPCR 22 ACC, 27 ACA, 6 NA ↓c Soon et al. (24, 57)
Microarray/RT-qPCR 10 ACC, 26 ACA, 21 NA ↓ Patterson et al. (58)
Microarray/RT-qPCR 25 ACC, 43 ACA, 10 NA ↓ Ozata et al. (47)
Microarray/RT-qPCR 12 ACCa, 6 ACA + validation cohort (18 ACCa, 10 ACA, 3 NA) ↓ Chabre et al. (59)
NGS 45 ACCa, 3 NA ↓ Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↓ Feinmesser et al. (61)
miR-335 Microarray/RT-qPCR 22 ACC, 27 ACA, 6 NA ↓ Soon et al. (24, 57)
TLDA 4 ACC, 9 ACA, 4 NA + validation cohort (n = 15) ↓ Schmitz et al. (63)
Microarray/RT-qPCR 12 ACCa, 6 ACA + validation cohort (18 ACCa, 10 ACA, 3 NA) ↓ Chabre et al. (59)
NGS 45 ACCa, 3 NA ↓ Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↓ Feinmesser et al. (61)
miR-214 TLDA 7 ACC, 19 ACA, 10 NA ↓ Tombol et al. (25, 62)
NGS 45 ACCa, 3 NA ↓ Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↓ Feinmesser et al. (61)
miR-375 TLDA 7 ACC, 19 ACA, 10 NA ↓ Tombol et al. (25, 62)
miR-511 TLDA id. ↓ id.
miR-100 Microarray/RT-qPCR 10 ACC, 26 ACA, 21 NA ↓ Patterson et al. (58)
miR-125b id. id. ↓ id.
Microarray/RT-qPCR 17 ACC, 29 ACA ↓ Feinmesser et al. (61)
miR-1974 Microarray/RT-qPCR 25 ACC, 43 ACA, 10 NA ↓ Ozata et al. (47)
miR-497 Microarray/RT-qPCR id. ↓ id.
NGS 45 ACCa, 3 NA ↓ Assie et al. (26)
Microarray/RT-qPCR 17 ACC, 29 ACA ↓ Feinmesser et al. (61)
miR-139-3p TLDA 4 ACC, 9 ACA, 4NA + validation cohort (n = 15) ↓ Schmitz et al. (63)
miR-675 TLDA id. ↓ id.
microRNAs highlighted in bold have been validated in several studies.
ACC, adrenocortical carcinoma; ACA, adrenocortical adenoma; NA, normal adrenal cortex.
↑ Upregulated, ↓ downregulated in ACC as compared to adenoma or normal adrenal cortices.
aThe ACC group was composed of aggressive (poor prognosis) and non-aggressive (good prognosis) ACC.
bOverexpressed in aggressive versus non-aggressive ACC.
cAssociated with shorter survival.
id, idem refers to the line above.
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was reported as a tumor suppressor in several other cancers. 
miR-503 was found underexpressed in hepatocellular carcinoma 
(HCC) and was shown to inhibit angiogenesis in vitro and in vivo 
by downregulating expression of both fibroblast growth factor 
2 (FGF2) and vascular growth factor A (VEGFA) (75). Low 
expression levels of miR-503 were associated with worse overall 
survival of HCC patients (76). Functional studies showed that 
miR-503 suppressed the proliferation of HCC cells by induction 
of G1 phase arrest through Rb-E2F signaling pathways (76). 
Furthermore, tumor suppressive effect of miR-503 was suggested 
in glioblastoma multiform (77). In this study, miR-503 was shown 
to exert its effect not only through suppression of cell prolifera-
tion by inducing G0/G1 cell cycle arrest and apoptosis but also 
through inhibition of cancer cell migration and tumor invasion. 
In addition, insulin-like growth factor-1 (IGF–1R) receptor 
mRNA was identified as a target of miR-503.
miR-210
Overexpression of miR-210 in ACC has been observed in five 
studies out of eight (Table 1). High miR-210 was found associ-
ated with ACC aggressiveness and poor prognosis (60). miR-210 
is a master miRNA in the cellular response to hypoxia (78). As 
hypoxia is a major hallmark of solid tumors, it is therefore not 
surprising that miR-210 is overexpressed in many tumors types. 
The expression of miR-210 is elevated in head and neck carci-
noma (79), lung adenocarcinoma (80), late-stage small cell lung 
cancer (81), glioma (82), malignant melanoma (83), pancreatic 
ductal adenocarcinomas (84), ovarian cancer (85), and renal 
cancer (86). The stem–loop of miR-210 is located in an intron 
of a non-coding RNA on chromosome 11p15.5 (87). miR-210 
is regulated by both HIF1α and HIF2α transcription factors 
(88, 89). However, Akt activation induces hypoxia-associated 
accumulation of miR-210 in a HIF-independent manner, sug-
gesting that several signaling pathways can upregulate miR-210 
in response to hypoxic stress (90).
miR-195
miR-195 is also a major miRNA deregulated in ACCs (Table 1). 
miR-195 is significantly downregulated in ACCs compared to 
ACAs and its low expression in ACCs is significantly associ-
ated with poor overall survival (57). miR-195 levels are also 
significantly downregulated in childhood adrenocortical tumors 
(46). miR-195 gene is located on the chromosome 17p13.1 and 
is a member of the miR-15/16/195/424/497 family of miRNAs. 
Numerous studies have suggested that miR-195 promotes apop-
tosis while inhibiting cell proliferation. Restoration of miR-195 
expression in the ACC cell line NCI-H295R impaired their 
proliferation in  vitro (47). miR-195 is aberrantly expressed in 
multiple types of cancers, including human breast cancer (91), 
glioblastoma multiforme (92), gastric cancer (93), human HCC 
(94), and bladder cancer (95). Cyclin D1, CDK6, and E2F3 were 
identified as direct targets, suggesting that miR-195 plays a role 
in regulating G1/S transition. In colorectal cancer, miR-195 was 
shown to target Bcl-2 and thereby to inhibit tumorigenicity 
through apoptosis (96). In breast cancer, the methylation state 
of CpG islands upstream of the miR-195/497 gene was found to 
be responsible for the downregulation of both miRNAs (91). A 
forced expression of miR-195 or miR-497 suppressed breast can-
cer cell proliferation and invasion. In this study, Raf-1 and Cyclin 
D1 were identified as direct targets of miR-195. In addition, 
miR-195 expression in breast cancer was found to be inversely 
correlated with malignancy.
miR-335
miR-335 was highly significantly downregulated in ACCs as 
compared to ACAs and normal adrenocortical tissue in several 
studies (Table 1). miR-335 has been shown to act as tumor sup-
pressor or oncogene depending on cancer types. These findings 
suggest a tissue-specific role for miR-335. miR-335 is located at 
7q32.2. It is downregulated in breast cancer (97, 98), while it is 
upregulated in colon cancer (99) and pediatric acute leukemia 
(100). The genetic deletion and epigenetic promoter hypermeth-
ylation occurring at miR-335 locus has been correlated with breast 
cancer metastases and ovarian cancer recurrence (98). In breast 
cancer, miR-335 suppresses metastasis and migration through 
targeting of the progenitor cell transcription factor SOX4 and 
extracellular matrix component tenascin C (101). More recently, 
miR-335 was shown to act as a tumor suppressor to regulate clear 
cell renal cell carcinoma cell proliferation and invasion through 
downregulation of BCL-W expression (102). Moreover, miR-335 
suppresses breast cancer cell migration by negatively regulating 
the HGF/c-Met pathway (103).
microRNAs Differentiating between 
Aggressive and Non-Aggressive ACC: The 
miR-506-514 and DLK1-MeG3 Clusters
Recent genomic studies led to the identification of two distinct 
molecular subgroups of ACC with different outcomes: the C1A 
group, associated with poor prognosis, and the C1B group, asso-
ciated with better prognosis (21, 26). Using Illumina sequencing 
to determine miRNA expression in 45 ACC, Assie et al. identified 
three ACC clusters characterized by three distinct miRNA profiles 
Mi1, Mi2, and Mi3. Mi1 and Mi2 clusters belong to the C1B group, 
while the Mi3 cluster characterizes the C1A group. Strikingly, 
the Mi1 cluster displayed the largest differences in miRNA 
expression relative to NA samples. This group was characterized 
by upregulation of 11 miRNAs belonging to the miR-506-514 
cluster located at Xq27.3. Interestingly, these observations were 
in agreement with those reported by Chabre et  al. in a small 
cohort of ACC [discovery cohort: 6 aggressive ACC (aACC, poor 
prognosis), 6 non-aggressive ACC (naACC, good prognosis) and 
6 ACA; validation cohort: 9 aACC, 9 naACC, and 10 ACA] (59). 
In this study, miR-508-3p, miR-509-3p, miR-513-3p, and miR-
514, which belong to the miR-506-514 cluster, were also found 
upregulated in naACC as compared to aACC. An oncogenic role 
for the miR-506-514 cluster was reported in melanoma where 
these miRNAs promote not only melanoma progression but also 
melanocyte transformation (104). The mechanisms underlying 
the upregulation of this oncogenic miRNA cluster in non-aggres-
sive ACCs (C1B group) then its downregulation in aggressive 
ACC (C1A group) remain to be determined. Along the same line, 
comparing the miRNAs related to melanoma early progression 
to those involved in metastasis, Mueller et al. identified miR-506 
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and miR-507 as upregulated during early progression and subse-
quently downregulated in metastatic colonization (105). One can 
speculate that the functions of sub-clusters of the miR-506-514 
cluster versus the full miR-506-514 cluster support shifting roles 
for various members depending on the stage of ACC progression. 
Identifying downstream targets of the miR-506-514 cluster may 
reveal important pathways contributing to ACC pathogenesis.
In humans, the DLK1-DIO3 genomic region, located on 
human chromosome 14 (14q32) contains the paternally expressed 
imprinted genes DLK1, RTL1, and DIO3 and the maternally 
expressed imprinted genes MEG3 and MEG8, and antisense 
RTL1. This region hosts, in addition to the two long intergenic 
RNAs MEG3 and MEG8, one of the largest miRNA clusters in 
the genome, with 53 miRNAs in the forward strand and one in 
the reverse strand (106). Assie et al. found downregulation of 38 
miRNAs belonging to the imprinted DLK1-MEG3 cluster located 
at 14q32.2 in the good prognosis group of ACC (Mi1 tumors) 
(26). LOH of chromosome arm 14q was detected in all Mi1 
tumors, associated with full methylation of MEG3 promoter. In 
line with these data, Chabre et al. reported that several miRNAs 
belonging to the DLK1-MEG3 (miR-370, miR-376a, miR-376b, 
miR-376c, miR-377, miR-379, miR-382, miR-411, miR-487a, 
miR-494, and miR495) were downregulated in non-aggressive 
ACC as compared to aggressive ACC (59). Quantitative PCR 
analysis further confirmed that miR-376a, miR-376b, and miR-
376c were significantly underexpressed in naACC. Using micro-
array expression and qRT-PCR assays, Teferedegne et al. found 
that increases in the expression of miR-376a correlated with 
the acquisition of tumorigenic phenotypes in cell lines of non-
human primates (107). miR-376a overexpression was associated 
with nodal metastasis in the progression of gastric cancer (108). 
Interestingly, overexpression of the DLK1-MEG3 was positively 
correlated with HCC stem cell markers and associated with poor 
survival rate in HCC patients (109). In another study, overex-
pression of miR-376c in ovarian cancer cells was found to block 
cisplatin-induced cell death (110). The investigators suggested 
that miR-376c enhances proliferation, survival, and chemoresist-
ance by targeting activin receptor-like kinase 7 (ALK7). The role 
of the DLK1-MEG3 cluster in ACC aggressiveness awaits further 
investigations.
Deregulation of the miRNA-Processing 
Machinery in Adrenocortical Cancer
In addition to genomic or transcriptional alterations, deregulated 
miRNA expression can arise from failure in miRNA biogenesis. 
Several studies have shown that miRNA expression is globally 
suppressed in cancer cells compared with normal tissue, suggest-
ing that miRNA biogenesis might be defective in cancer (39). 
A decreased expression of Dicer1 and Drosha has been reported 
in lung and ovarian cancers (111, 112). In addition, low Drosha 
or Dicer1 expression levels were associated with advanced tumor 
stage and poor clinical outcome in patients with ovarian cancer 
(112). On the contrary, Dicer1 overexpression was reported in 
melanomas (113) and was associated poor survival in colorectal 
cancer (114). Higher expression of Drosha was found in cervi-
cal squamous cell carcinomas (115) and epithelial skin cancers 
(116). Its overexpression was associated with poor prognosis in 
esophageal cancer (117). These variations of Dicer1 and Drosha 
expression levels among different tumor types suggest that 
miRNA-processing complexes act as tumor suppressors or onco-
genes depending on cellular context. In adrenocortical cancer, 
two studies analyzed Tarbp2, Dicer1, and Drosha expression in 
ACA and ACC. Using RT-qPCR, Caramuta et al. reported a sig-
nificant overexpression of Tarbp2, Dicer1, and Drosha transcripts 
in carcinomas compared with adenomas or NA cortices (43 ACA, 
30 ACCs, and 9 NA cortices) (48). In addition, mRNA expression 
of Tarbp2, but not Dicer1 and Drosha could discriminate between 
ACAs and ACCs. Copy number gain of the Tarbp2 gene was 
observed in 57% of the ACCs analyzed in this study. Inhibition 
of Tarbp2 expression in NCI-H295R cells resulted in a decreased 
cell proliferation and induction of apoptosis. Tarbp2 and Dicer1 
were demonstrated as targets of miR-195 and miR-497, two 
miRNAs downregulated in ACC, suggesting that miRNAs might 
contribute to deregulation of their own biogenesis. de Sousa et al. 
analyzed Tarbp2 and Dicer1 expression in a cohort of 75 ACAs 
and 79 ACCs (118). Immunohistochemical analysis revealed that 
Dicer1 protein overexpression was found in 49% of ACCs and 32% 
of ACAs, while its mRNA was overexpressed in 60% of ACCs and 
23% of ACAs. Nevertheless, the authors reported that metastatic 
ACC were characterized by a weak Dicer1 expression as com-
pared to their non-metastatic counterparts. Furthermore, a weak 
Dicer1 expression was associated with reduced disease-free and 
overall survival. In contrast to Caramuta et al. study, no signifi-
cant differences were found between ACCs and ACAs in terms of 
Tarbp2 protein or mRNA levels. The reasons for these discrepan-
cies between the two studies remain unclear. They might be due 
to the size and the heterogeneity of the cohorts. Another regulator 
of miRNA biogenesis, LIN28, has been studied in adrenocortical 
tumors (119). LIN28 is an RNA-binding protein that binds to 
let-7 miRNA precursors (pri- and pre-let-7) and blocks their pro-
cessing by Drosha in the nucleus and by Dicer in the cytoplasm 
(120). LIN28 was found underexpressed in aggressive ACC as 
compared to their non-aggressive counterparts (119). In the same 
study, Faria et al. reported that both weak expression of LIN28 
and overexpression of miR-9, a negative regulator of LIN28, were 
associated with poor outcome of ACC patients. Nevertheless, a 
direct functional interaction between LIN28 and miR-9 was not 
investigated. When analyzing the global expression profile of 
miRNAs in the ACC cohort studied by Assie et al., it seems that 
miRNAs are rather overexpressed in the poor prognosis group 
as well as in a subpopulation of good prognosis group (26). 
Indeed, among the significantly deregulated miRNAs in ACC 
with poor outcome (C1A group), 86% were found upregulated 
and 14% were downregulated (Mi3 cluster). In the C1B group 
with good prognosis, 85% of the miRNAs were upregulated and 
15% were downregulated in the Mi2 cluster, while only 45% were 
upregulated and 55% were downregulated in the Mi1 cluster. 
Chabre et al. also observed that all the discriminatory miRNAs 
between aggressive and non-aggressive ACC were upregulated in 
aggressive ACCs (59). Putting all these data together, it seems that 
the contribution of the miRNA-processing machinery disruption 
to the global deregulation of miRNA expression in ACC needs 
further clarifications.
TABLe 2 | Deregulated circulating microRNAs in patients with 
adrenocortical cancer.
validated  
miRNA in ACC 
compared to  
ACA or NA
Sample type and 
cohort composition
Signature Reference
miR-483-5p Serum, 23 ACC, 14 ACA, 
9 NA
↑a,b,c Chabre et al. (59)
Plasma, 13 ACC, 12 ACA ↑ Szabo et al. (51, 129)
Serum, 17 ACC, 22 ACA ↑ Patel et al. (128)




miR-34a Serum, 17 ACC, 22 ACA ↑ Patel et al. (128)
miR-195 Serum, 23 ACC, 14 ACA, 
9 NA
↓a,c Chabre et al. (59)
miR-335 Serum, 23 ACC, 14 ACA, 
9 NA
↓a Chabre et al. (59)
ACC, adrenocortical carcinoma; ACA, adrenocortical adenoma; NA, normal adrenal 
cortex.
↑ Upregulated, ↓ downregulated in the serum or plasma of patients with ACC as 
compared to patients with adenoma or healthy subjects.
aThe ACC group was composed of aggressive (poor prognosis) and non-aggressive 
(good prognosis) ACC.
bOverexpressed in the serum from patients with aggressive versus patients with non-
aggressive ACC.
cAssociated with shorter survival and recurrence risk.
Circulating microRNA levels were determined by RT-qPCR in the three cited studies.
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CiRCULATiNG microRNAs AS POTeNTiAL 
NON-iNvASive DiAGNOSTiC AND 
PROGNOSTiC BiOMARKeRS iN ACC
Since the discovery of cell-free circulating miRNAs, numer-
ous studies have reported that specific miRNA levels in body 
fluids reflect various disease states (42). Although the precise 
mechanism of miRNA release into the extracellular environ-
ment is not completely elucidated, some miRNAs are probably 
released as a result of normal or pathology-associated cell death 
(41, 121). Other cellular miRNAs were shown to be released 
into body fluids through active secretion. Notably, a ceramide-
dependent secretory pathway that involves sphingomyelinase 
2 has been described (122). Circulating miRNAs are either 
encapsulated in small vesicles that are referred to as microvesi-
cles or exosomes depending on their size, or complexed to 
HDL and RNA-binding proteins. Nevertheless, Turchinovich 
et al. reported that most extracellular miRNAs in blood plasma 
and cell culture conditioned media are not associated with 
exosomes or microvesicles but are bound to Ago2, a component 
of the RISC complex (123). The role of HDL-mediated miRNA 
transport in the context of adrenocortical tumorigenesis 
deserves further investigations as HDL may also function as 
a source of ApoA1-dependent selective uptake of cholesterol 
in steroidogenic cells through the scavenger receptor SR-B1 
(124). A potential connection between cholesterol uptake and 
miRNA internalization in adrenocortical cells remains an open 
and fascinating question.
The field of circulating miRNA research in ACC is emerg-
ing and we are still far from having a clear picture. The transfer 
to the clinic of circulating miRNA-based test requires the 
establishment and implementation of standardized operating 
procedures. Unspecific fluctuations of circulating miRNAs 
may arise upon different serum/plasma preparation methods, 
different storage conditions of samples, and the presence of 
hemolysis (125–127). Another major concern is the potential 
interference of the therapy with circulating miRNA levels that 
may confound the interpretation of the results. Prospective 
studies in which blood samples will be timely collected before 
and after treatment of ACC patients are needed. Three studies 
analyzed circulating miRNA levels in ACC patients (Table 2). 
All three studies reported an increase in miR-483-5p in ACC 
patients, which seems to accompany the previously identified 
increase of miR-483-5p in tumor tissue (59, 128, 129). However, 
there are substantial differences in the findings of these studies, 
which may be in part due to the different blood material used, 
i.e., serum or plasma and the normalization strategies. Chabre 
et  al. spiked-in C. elegans cel-miR-39 not only to monitor the 
efficiency of RNA extraction but also to use it as a normaliza-
tion miRNA. Based on the identification of deregulated levels 
of miR-195, miR-335, miR-139-5p, miR-376a, and miR-483-5p 
(Table  2), they assessed their potential diagnostic value. The 
most informative miRNA for the discrimination of ACA from 
ACC patients was miR-195 [area under curve (AUC) = 0.948, 
95% CI: 0.819–0.994, p < 0.0001]. miR-195 could detect indi-
viduals with adrenocortical cancer with 90.9% sensitivity and 
100% specificity. miR-335 and miR-376a were also good markers 
of malignancy with an AUC of 0.837, and 0.811, respectively. 
Although miR-139-5p displayed high sensitivity for the dis-
crimination of ACA from ACC patients (87.5%), its specificity 
was moderate (65%, AUC  =  0.714, p  =  0.023). Importantly, 
miR-483-5p could distinguish non-aggressive ACC from aggres-
sive ACC patients with 85.7% sensitivity and 100% specificity 
(AUC = 0.929, 95% CI: 0.741–0.994, p < 0.0001). Moreover, low 
levels of miR-195 and high levels of miR-483-5p were predic-
tive of recurrence risk in ACC patients. Using plasma samples 
and endogenous miR-16 as a reference, Szabo et  al. identified 
hsa-miR-100, hsa-miR-181b, hsa-miR-184, hsa-miR-210, and 
hsa-miR-483-5p miRNAs as significantly differentially expressed 
between ACA and ACC patient plasma samples (129). By 
combining endogenous hsa-miR-16 and spiked-in cel-miR-39, 
they found hsa-miR-181b and hsa-miR-483-5p as significantly 
differentially expressed. The dCThsa-miR-210–dCThsa-miR-181b and the 
dCThsa-miR-100/dCThsa-miR-181b pairs yielded the highest AUC values 
(0.87 and 0.85, respectively). In Patel’s study, it was found that 
the levels of miR-34a were increased in the serum of patients 
with ACC, while miR-34a was reported to be decreased in ACC 
tumors (128). Along the same line, Chabre et al. observed that 
miR-376a was significantly upregulated in ACC tumors, while 
it was significantly downregulated in the serum of patients 
with ACC. Opposite differential expression profiles of miRNAs 
in the circulation compared to parental cells are increasingly 
reported (130). These observations raise the question of an active 
FiGURe 3 | Schematic representation of the potential cross-talk between adrenocortical cancer cells and cells of the tumor microenvironment 
(TMe). By targeting cells of the TME, adrenocortical cancer cell-derived exosomes could favor stimulation of angiogenesis, production of pro-inflammatory 
cytokines, alterations of the extracellular matrix, and generation of a pre-metastatic niche. The TME-derived exosomes (dashed lines) could enhance growth and 
survival of cancer cells, promote invasion and induction of epithelial to mesenchymal transition, and also drug resistance. MBV, multivesicular body.
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mechanism by which selected miRNAs are promoted toward the 
extracellular space. Given the small cohorts used these studies, 
validation of circulating miRNAs as biomarkers for adrenocor-
tical cancer requires an in-depth analysis in larger cohort of 
samples. Combinatorial use of multiple miRNAs should improve 
the sensitivity and specificity of biomarkers panels.
ADReNOCORTiCAL CANCeR  
CeLL-DeRiveD eXOSOMeS: PLAYeRS  
iN THe COMMUNiCATiON wiTH THe 
TUMOR MiCROeNviRONMeNT?
Although the release of apoptotic bodies during apoptosis has 
long been recognized (131), the fact that healthy cells also shed 
vesicles from their plasma membrane has only recently become 
appreciated. Numerous studies are beginning to decipher 
the molecular mechanisms of exosomes sorting and release. 
Notably, the content of cancer cell-derived exosome differs from 
exosomes derived from normal healthy cells and cancer cells 
have an increased rate of exosome release (132). The concept 
that exosomes are signaling entities in the cross-talk between 
various cell types is expanding (133). One can anticipate that 
exchange of exosomes between adrenocortical cancer cells and 
their neighboring components in the tumor microenvironment 
(TME), such as vascular endothelial cells, immune cells, and 
fibroblasts, might occur (Figure  3). The cellular origin of the 
multiple significantly deregulated miRNA in ACC tumor tissue 
as well as in the serum of the patients has not been deciphered 
so far. The expression profiles of miR-335, miR-195, miR-376a, 
miR-376b, miR-376c, miR-139-5p, and miR-483-5p in the 
NCI-H295R cell line were similar to their expression in the 
patients ACC samples, suggesting that their deregulation occurs 
in cancer cells (59). Increased circulating levels of miR-483-5p 
paralleled its marked upregulation in ACC. Nevertheless, defin-
ing the cellular localization of the other deregulated miRNA in 
ACC by performing in  situ hybridization may help to unravel 
the potential interaction between ACC cancer cells and their 
surroundings and also the relationship between intratumoral 
and circulating miRNAs. Luga et  al. reported a key role for 
cancer-associated fibroblast-derived exosomes in mobilizing 
autocrine Wnt-planar cell polarity (PCP) signaling in breast can-
cer cells to stimulate invasive behavior and metastasis in animal 
models (134). Transfer of exosomal miRNAs to endothelial cells 
has been shown to disrupt the vascular endothelial barrier by 
targeting the tight junction protein ZO-1 during early breast pre-
metastatic niche formation (135). A seminal study performed by 
the group of Liberman demonstrated that exosomes released by 
metastatic cancer cells can transfer metastatic capabilities to non-
metastatic cells. This transformation is directed by the miR-200 
family that is known to mediate the mesenchymal-to-epithelial 
transition (136). The exchange of exosomal miR-21 and miR-155 
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between neuroblastoma cells and human monocytes has been 
implicated in the development of resistance to chemotherapy 
(137). All these observations open new perspectives in the field 
of exosome-mediated cell-to-cell communication within the 
TME in ACC.
SiLeNCiNG AND ReCOveRY OF ALTeReD 
microRNAs: A FUTURe THeRAPeUTiC 
APPROACH iN ADReNOCORTiCAL 
CANCeR
microRNAs are at the center of a complex combinatorial code 
regulating gene expression. Thus, identifying the relationships 
between miRNA signatures and adrenocortical cancer could 
help to understand the mechanisms behind the pathological 
processes and to develop therapeutic strategies. The biosynthe-
sis, maturation, and activity of miRNAs can be manipulated 
by specific oligonucleotides that are complementary to mature 
miRNAs (138). Overexpression of miRNAs can be triggered 
by using synthetic miRNA mimics. Conversely, overexpressed 
miRNAs can be silenced by antagomiRs or miRNA sponges to 
restore miRNA balance in cancer networks (139). For example, 
inhibition of miR-21 and miR-17-92 was associated with reduced 
tumor growth, invasion, angiogenesis, and metastasis (140, 141). 
The therapeutic potential of miR-122 antagonist, miravirsen, in 
the treatment of Hepatitis C was evident from a multi-centric 
phase II trial (142). Although such findings are exciting, targeted 
miRNA therapeutics remain in the early stages of development 
and are essentially limited to in  vitro and murine models of 
cancer. The development of relevant animal models of ACC is 
essential to the preclinical testing of miRNA-based therapies. On 
the other hand, though miRNAs possess tremendous therapeutic 
potential for cancer, a major concern remains their delivery 
system that may induce off-target effects. Lipid-based vehicles, 
viral systems, and cationic polymers are the main delivery tools 
for miRNA-based therapeutics (143). Each of these strategies has 
its own challenges and still needs improvements to address prob-
lems, such as cytotoxicity, immunogenicity, and low efficiency. 
Due to their natural role in miRNA secretion and shuttling 
between different cells, exosomes are of great interest in miRNA 
therapeutics. Their non-synthetic nature potentiates them for 
more efficient and non-immunogenic delivery of cargo while 
they maintain the cargo integrity and stability. Moreover, exo-
somal membranes contain proteins that have specific receptors 
on the surface of recipient cells. Therefore, they can selectively 
target cell types of interest and modifying their miRNA contents. 
Two delivery systems using liposome formulated miRNAs or 
miRNAs packaged in EnGeneIc Delivery Vehicles (EDVs) (144, 
145) have reached the clinic and are currently under evaluation 
in cancer clinical trials. Recently, Glover et al. first reported that 
systemic administration of miR-7-containing EDV reduces ACC 
xenograft growth through the targeting of Raf-1 proto-oncogene 
and mechanistic target of rapamycin (mTOR) (49). This work is 
the first study investigating the therapeutic potential of miRNAs 
in ACC and many others should be expected.
CONCLUSiON
The discovery of miRNAs has considerably changed our under-
standing of gene regulation and new findings over the last decade 
have established that miRNA are key players in cancer molecular 
biology. Deregulations of miRNAs expression and activity are 
important steps in the development of many cancers, including 
adrenocortical cancer. On the basis of expression profiling of 
miRNA in ACC, several groups have identified miRNAs ena-
bling diagnosis and prognosis of ACC. These findings need to be 
validated in larger cohorts and in prospective studies. Another 
important question for the management of ACC is the possibility 
of predicting patient response to therapy. Identification of specific 
miRNAs as significant indicators for response to mitotane or 
chemotherapy may guide the clinicians and provide an oppor-
tunity for personalized medicine. To improve our knowledge as 
to the role of miRNAs in ACC pathogenic pathways, functional 
effects of specific miRNAs need more comprehensive and 
thorough studies. The occurrence of miRNAs in the serum and 
plasma of ACC patients lays the groundwork for their develop-
ment as minimally invasive biomarkers. The fact that miRNAs 
can function as cellular master regulators, show broad activity 
across multiple cancer types, and appear to specifically inhibit 
metastasis suggests that they could be used as therapeutic agents 
in cancers for which there are no or few treatment options, such 
as ACC. Nevertheless, a number of scientific and technical 
considerations must be addressed before we could reach 
these promising prospects.
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